Arrowhead Pharmaceuticals (ARWR) is trading higher as investors continue to react to newly presented long-term efficacy and safety data for investigational plozasiran across a range of hypertriglyceridemia populations. The company’s update emphasized durable triglyceride lowering over two years, keeping attention on plozasiran’s commercial and regulatory potential in larger cardiometabolic indications. (arrowheadpharma.com)

In the long-term open-label extension dataset highlighted by the company, patients with severe hypertriglyceridemia achieved an 83% median triglyceride reduction, and 96% reached triglycerides below 500 mg/dL, a commonly referenced risk threshold for acute pancreatitis. The company also pointed to a consistent safety profile in the longer-duration follow-up, which investors typically view as important for chronic cardiometabolic use. (arrowheadpharma.com)

The market is pricing in a catalyst-heavy 2026 for Arrowhead, with management previously pointing to mid-2026 timing for completion of the blinded portions of key registrational studies and a planned regulatory filing timeline for plozasiran in severe hypertriglyceridemia later in 2026. With the next earnings date also on the calendar, traders often re-rate the stock as major clinical and regulatory milestones come into clearer view. (tipranks.com)

Next focus areas include additional plozasiran clinical updates tied to the ongoing Phase 3 program and any incremental disclosure around launch execution and payer access for Arrowhead’s commercial products. Conference commentary and study-timing updates can also move the shares as investors recalibrate how quickly Arrowhead can translate the cardiometabolic pipeline into approvals and revenue. (finance.yahoo.com)